EXUMA
Live / Applied — Second extension granted (statement of use) (as of 06 May 2025)
What this means for you
Not registered yet, but its 11 Aug 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97544808
- Mark type
- Stylized text
- Filed
- 11 Aug 2022
- Published for opposition
- 12 Mar 2024
- Attorney of record
- Alison M. Caless
Goods and services
- Class 005 — Pharmaceuticals: Medicines for human purposes in the nature of pharmaceutical preparations for gene and cell therapy, immunotherapy and the treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, and infectious diseases; biological preparations for medical treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, gene and cell therapy, and infectious diseases for humans and animals; medical biological tissue cultures and viruses for the prevention and treatment of cancer for humans and animals; drug products in the nature of pharmaceutical preparations for immunotherapy and the treatment of cancer, immunological diseases and disorders, genetic disorders, rare diseases, and infectious diseases for humans and animals
- Class 040 — Treatment of materials: Custom manufacturing of medical products in the nature of biological tissue, blood, viruses, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy, including gene therapy, CAR T cell therapy, and cell therapy; custom manufacturing of biological preparations for the treatment of cancer
- Class 042 — Scientific and technological services: Bacteriological research; biological research; medical and scientific research, namely, conducting clinical trials for others; medical research; virological research; medical laboratory services; scientific research; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs, namely, processing blood to isolate leukocytes for the creation of immunotherapies; scientific and medical research and development of pharmaceutical preparations and drugs; computer programming in relation to medicine and medical research; research in the field of stem cells
Owner
- Exuma Biotech Corp., West Palm Beach, FL, US
- Exuma Biotech Corp., West Palm Beach, FL, US
Prosecution history
- 07 Nov 2025 — TEAS STATEMENT OF USE RECEIVED
- 07 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 May 2025 — SOU EXTENSION 2 GRANTED
- 06 May 2025 — SOU EXTENSION 2 FILED
- 06 May 2025 — SOU TEAS EXTENSION RECEIVED
- 06 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Nov 2024 — SOU EXTENSION 1 GRANTED
- 06 Nov 2024 — SOU EXTENSION 1 FILED
- 06 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 07 May 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 12 Mar 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Mar 2024 — PUBLISHED FOR OPPOSITION
- 21 Feb 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Feb 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 05 Feb 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER